Across TCGA pan-cancer cohorts, ZACN Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZACN data layer compared with 25 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZACN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZACN expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
BRCA, READ, and UCEC are the cancer types where ZACN Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.